Skip to main content
Fig. 5 | BMC Complementary Medicine and Therapies

Fig. 5

From: Preclinical studies of toxicity and anti-cholangiocarcinoma activity of the standardized capsule formulation of Atractylodes lancea (Thunb.) DC

Fig. 5

The levels of VEGF expression CCA-xenografted nude mice following treatment with CMC-AL at high-, medium-, and low-dose levels (5000, 3000 and 1000 mg/kg body weight, respectively), cisplatin (reference control: 40 mg/kg body weight) and untreated control. Quantification of the percentage of VEGF level is shown. *P = 0.01 and **P = 0.001

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us